OVERVIEW
Human epidermal growth factor receptor 2 (HER2)-targeted therapy plays an essential role in the treatment of HER2-positive breast cancer. In the past year, 5 biosimilars of the HER2-targeted monoclonal antibody trastuzumab have received FDA approval, with the aim of reducing costs and enhancing access to these important therapies. These biosimilar products have undergone rigorous testing to demonstrate that they are highly similar to the trastuzumab reference product, showing no clinically meaningful differences in terms of safety, purity, and potency. The process through which biosimilar products are developed and regulated differs substantially from that of reference biologic products. In this symposium, an expert on biosimilars in oncology will review the science and regulation of biosimilars, discuss nuances of integrating biosimilars into clinical practice, and share ongoing challenges and future opportunities.
GOAL STATEMENT
The goal of this activity is to improve the knowledge of the members of the oncology care team regarding the safe and effective use of biosimilars and to improve confidence in communicating and coordinating among the oncology care team in managing patients who receive biosimilars for the treatment of breast cancer.
LEARNING OBJECTIVES
Have increased knowledge regarding the
- Similarities and differences in characteristics and approval process between biosimilars and their reference products
- Key data associated with biosimilars used for the treatment of HER2-positive breast cancer
Have greater competence related to
- Educating patients about biosimilars
- Coordinating with other members of the oncology care team to incorporate biosimilars into the management of patients with HER2-positive breast cancer
1.0 CME Credit Available
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 |
 |
For Physicians
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Nurses
Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs.
For Pharmacists
Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-20-285-L01-P).